Hepregen Corporation Receives National Science Foundation Grant Under SBIR Phase II-B Program

June 27, 2012

HEPREGEN CORPORATION RECEIVES   

NATIONAL SCIENCE FOUNDATION GRANT

UNDER SBIR PHASE II-B PROGRAM

Grant Funding will Support Continued Development of HepatoPac™ for Advanced Toxicity Screening and Drug Discovery

Medford, MA, June 27, 2012 - Hepregen Corporation, a leading provider of bioengineered solutions for drug development, announced today that the company has received a grant for $500,000 from the National Science Foundation under the SBIR Phase II-B Program. This latest award, along with a Challenge Grant from the National Institutes of Health (NIH), a Mass Life Science Center Small Business Matching Grant and earlier grant awards, total nearly $3.0M in state and federal non-dilutive financing.

"As an enabling technology, the HepatoPac™ platform provides high-value information to the pharmaceutical industry," commented Bonnie Fendrock, Hepregen's President and CEO. "Creating predictive in vitro models is an important area of opportunity in drug development. This NSF grant allows us to expand our HepatoPac™ offering to include other preclinical species, which is important in refining and reducing animal studies during drug development. We are very excited by the work that we have done to date with pharmaceutical companies who recognize the potential of HepatoPac™, not only as a predictive platform, but also as an enabling technology in drug discovery."

The NSF grant provides further support to Hepregen for the project entitled, "Development of a Human Liver Platform for High-Throughput Screening of Drug-Induced Liver Injury and Drug-Drug Interaction." Principal Investigator of the grant, Dr. Okechukwu Ukairo, Sr. Principal Scientist at Hepregen, will direct the further development of Human HepatoPac™ as a product offering and optimize additional in vitro preclinical species HepatoPac™ platforms.

Eighty percent of all drugs are metabolized or detoxified in the liver; therefore, the safety of drugs as they travel through the liver is of prime importance to the pharmaceutical industry. Hepregen is developing a unique, bioengineered microliver platform as a highly functional model of the liver in vivo. The potential of Hepregen's HepatoPac™ platform is to provide higher content data for faster, more informed decision making, while offering significant value in the drug development process for better and safer medicines.

About Hepregen Corporation 

Hepregen's mission is to translate the value of its technology platform to improve the safety and efficacy of drugs in development with greater economic efficiency and significant impact on patients' lives. The company is focused on advancing and commercializing its microliver platform, HepatoPac™, into the drug-development pipeline of pharmaceutical and biotechnology companies. Hepregen's platform technology offers the potential to deliver a breakthrough technology for toxicity screening and a new platform for drug discovery. It combines sophisticated biological and engineering technologies to create an in vitro liver model which closely mimics many key functions of the human liver. In 2008, Battelle Ventures spun out Hepregen Corporation from the Massachusetts Institute of Technology (MIT), and led the company's Series A financing.

 

Media Contact:

Amanda Murphy 

LaVoie Group 

Office: 978-745-4200 x107

amurphy@lavoiegroup.com

www.lavoiegroup.com

Business Development/Investor Contact:

Bonnie Fendrock

Hepregen Corporation

781-391-0205 x101

bfendrock@hepregen.com

www.hepregen.com

BioFlash

Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.